Literature DB >> 34975350

BayesCTDesign: An R Package for Bayesian Trial Design Using Historical Control Data.

Barry S Eggleston1, Joseph G Ibrahim2, Becky McNeil1, Diane Catellier1.   

Abstract

This article introduces the R (R Core Team 2019) package BayesCTDesign for two-arm randomized Bayesian trial design using historical control data when available, and simple two-arm randomized Bayesian trial design when historical control data is not available. The package BayesCTDesign, which is available on CRAN, has two simulation functions, historic_sim() and simple_sim() for studying trial characteristics under user defined scenarios, and two methods print() and plot() for displaying summaries of the simulated trial characteristics. The package BayesCTDesign works with two-arm trials with equal sample sizes per arm. The package BayesCTDesign allows a user to study Gaussian, Poisson, Bernoulli, Weibull, Lognormal, and Piecewise Exponential (pwe) outcomes. Power for two-sided hypothesis tests at a user defined alpha is estimated via simulation using a test within each simulation replication that involves comparing a 95% credible interval for the outcome specific treatment effect measure to the null case value. If the 95% credible interval excludes the null case value, then the null hypothesis is rejected, else the null hypothesis is accepted. In the article, the idea of including historical control data in a Bayesian analysis is reviewed, the estimation process of BayesCTDesign is explained, and the user interface is described. Finally, the BayesCTDesign is illustrated via several examples.

Entities:  

Keywords:  Bayesian statistics; R; clinical trials; historical controls; power prior

Year:  2021        PMID: 34975350      PMCID: PMC8715862          DOI: 10.18637/jss.v100.i21

Source DB:  PubMed          Journal:  J Stat Softw        ISSN: 1548-7660            Impact factor:   6.440


  9 in total

1.  A practical guide to Bayesian group sequential designs.

Authors:  Thomas Gsponer; Florian Gerber; Björn Bornkamp; David Ohlssen; Marc Vandemeulebroecke; Heinz Schmidli
Journal:  Pharm Stat       Date:  2013-08-24       Impact factor: 1.894

2.  Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions-A calibration approach.

Authors:  Annette Kopp-Schneider; Manuel Wiesenfarth; Ruth Witt; Dominic Edelmann; Olaf Witt; Ulrich Abel
Journal:  Biom J       Date:  2018-09-02       Impact factor: 2.207

3.  Bayesian clinical trial design using historical data that inform the treatment effect.

Authors:  Matthew A Psioda; Joseph G Ibrahim
Journal:  Biostatistics       Date:  2019-07-01       Impact factor: 5.899

4.  A practical Bayesian adaptive design incorporating data from historical controls.

Authors:  Matthew A Psioda; Mat Soukup; Joseph G Ibrahim
Journal:  Stat Med       Date:  2018-07-22       Impact factor: 2.373

Review 5.  Use of historical control data for assessing treatment effects in clinical trials.

Authors:  Kert Viele; Scott Berry; Beat Neuenschwander; Billy Amzal; Fang Chen; Nathan Enas; Brian Hobbs; Joseph G Ibrahim; Nelson Kinnersley; Stacy Lindborg; Sandrine Micallef; Satrajit Roychoudhury; Laura Thompson
Journal:  Pharm Stat       Date:  2013-08-05       Impact factor: 1.894

6.  The power prior: theory and applications.

Authors:  Joseph G Ibrahim; Ming-Hui Chen; Yeongjin Gwon; Fang Chen
Journal:  Stat Med       Date:  2015-09-07       Impact factor: 2.373

7.  Bayesian design of a survival trial with a cured fraction using historical data.

Authors:  Matthew A Psioda; Joseph G Ibrahim
Journal:  Stat Med       Date:  2018-06-25       Impact factor: 2.373

8.  dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials.

Authors:  A Toumazi; E Comets; C Alberti; T Friede; F Lentz; N Stallard; S Zohar; M Ursino
Journal:  Comput Methods Programs Biomed       Date:  2018-01-31       Impact factor: 5.428

9.  Bayesian methods in clinical trials: a Bayesian analysis of ECOG trials E1684 and E1690.

Authors:  Joseph G Ibrahim; Ming-Hui Chen; Haitao Chu
Journal:  BMC Med Res Methodol       Date:  2012-11-29       Impact factor: 4.615

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.